1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol has been researched along with cardiovascular agents in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Medina, M; Sánchez-Salvatori, MA; Vidrio, H | 1 |
| Brett, RR; Kane, KA; Kennedy, S; Mair, KM; Pyne, NJ; Pyne, S; Robinson, E | 1 |
2 other study(ies) available for 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol and cardiovascular agents
| Article | Year |
|---|---|
Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats.
Topics: Animals; Anti-Arrhythmia Agents; Baroreflex; Blood Pressure; Cardiovascular Agents; Dose-Response Relationship, Drug; Dronabinol; Excitatory Amino Acid Antagonists; Heart Rate; Hemodynamics; Male; Oxidopamine; Rats; Rats, Wistar; Sympatholytics; Vagotomy | 1996 |
Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery.
Topics: Animals; Arachidonic Acids; Calcium Channel Blockers; Cardiovascular Agents; Cell Line; Coronary Vessels; Dronabinol; Endocannabinoids; Humans; Indoles; Indomethacin; Lysophospholipids; Male; Polyunsaturated Alkamides; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Sphingosine; Vasodilation | 2010 |